What is Entero Therapeutics's earnings per share (EPS)?

Entero Therapeutics (ENTO) reported diluted earnings per share of $-5.33 for fiscal year 2024. This represents a 88.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Entero Therapeutics Financials

ENTO

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Entero Therapeutics (ENTO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Entero Therapeutics passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.51x

For every $1 of reported earnings, Entero Therapeutics generates $0.51 in operating cash flow (-$9.2M OCF vs -$18.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$15.6M

YoY+1.1%

Entero Therapeutics's EBITDA was -$15.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1.1% from the prior year.

Net Income

-$18.1M

YoY-14.3%

Entero Therapeutics reported -$18.1M in net income in fiscal year 2024. This represents a decrease of 14.3% from the prior year.

EPS (Diluted)

$-5.33

YoY+88.9%

Entero Therapeutics earned $-5.33 per diluted share (EPS) in fiscal year 2024. This represents an increase of 88.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$163K

YoY-95.6%

5Y CAGR-1.4%

Entero Therapeutics held $163K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+1.5%

Entero Therapeutics had 2M shares outstanding in fiscal year 2024. This represents an increase of 1.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$904K

YoY-82.0%

5Y CAGR-36.4%

Entero Therapeutics invested $904K in research and development in fiscal year 2024. This represents a decrease of 82.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ENTO Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$904K-82.0%	$5.0M-42.6%	$8.8M-48.4%	$17.0M+188.6%	$5.9M-32.2%	$8.7M
SG&A Expenses	$14.7M+37.1%	$10.7M-10.4%	$12.0M-34.8%	$18.4M+152.0%	$7.3M+20.3%	$6.1M
Operating Income	-$15.6M+0.9%	-$15.8M-24.4%	-$12.7M+78.5%	-$59.1M-123.4%	-$26.4M-79.3%	-$14.7M
Interest Expense	N/A	$22K+41.5%	$16K+41.3%	$11K-99.8%	$5.8M+1246.0%	$434K
Income Tax	N/A	N/A	N/A	$0	$0	$0
Net Income	-$18.1M-14.3%	-$15.8M-8.0%	-$14.6M+75.0%	-$58.5M-79.2%	-$32.7M-115.3%	-$15.2M
EPS (Diluted)	$-5.33+88.9%	$-47.88	$-416.94+79.0%	$-1988.53	$-14.68	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$7K-37.2%	$11K-32.8%	$16K	N/A	$207K-5.7%	$220K-60.4%	$555K	N/A
SG&A Expenses	$928K+47.7%	$628K-22.0%	$806K	N/A	$1.7M-47.4%	$3.2M-62.5%	$8.5M	N/A
Operating Income	-$935K-46.3%	-$639K+22.2%	-$821K	N/A	-$1.9M+44.8%	-$3.4M+62.3%	-$9.1M	N/A
Interest Expense	N/A	N/A	$18K	N/A	-$229-5.0%	-$218-100.3%	$66K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$4.3M+128.6%	-$14.9M	N/A
Net Income	-$1.2M-15.5%	-$998K+20.7%	-$1.3M	N/A	-$2.6M+70.7%	-$8.8M-258.2%	$5.6M	N/A
EPS (Diluted)	$-0.75-257.1%	$-0.21+25.0%	$-0.28	N/A	$-1.76+54.4%	$-3.86-1115.8%	$0.38	N/A

ENTO Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$85.4M+1140.8%	$6.9M+26.5%	$5.4M-53.9%	$11.8M-8.8%	$12.9M+45.2%	$8.9M
Current Assets	$83.5M+1584.3%	$5.0M+45.2%	$3.4M-63.8%	$9.4M+19.8%	$7.9M+130.9%	$3.4M
Cash & Equivalents	$163K-95.6%	$3.7M+172.3%	$1.4M-83.5%	$8.2M+36.1%	$6.1M+3348.4%	$176K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$93K	$0-100.0%	$551K-79.1%	$2.6M
Goodwill	$1.7M0.0%	$1.7M0.0%	$1.7M-11.9%	$1.9M-6.9%	$2.1M+8.9%	$1.9M
Total Liabilities	$89.3M+2621.9%	$3.3M+21.6%	$2.7M-86.2%	$19.6M+26.0%	$15.6M+263.2%	$4.3M
Current Liabilities	$27.5M+779.1%	$3.1M+26.2%	$2.5M-79.8%	$12.3M-20.9%	$15.5M+262.7%	$4.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$3.9M-207.6%	$3.6M+31.4%	$2.7M+135.1%	-$7.8M-196.2%	-$2.6M-157.2%	$4.6M
Retained Earnings	-$202.4M-9.8%	-$184.3M-9.4%	-$168.5M-9.5%	-$153.9M-61.4%	-$95.4M-52.1%	-$62.7M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$135.4M+59.1%	$85.1M-0.2%	$85.2M-0.2%	$85.4M-0.5%	$85.8M-0.5%	$86.3M-5.3%	$91.1M+1224.0%	$6.9M
Current Assets	$87.7M+5.3%	$83.3M-0.2%	$83.5M0.0%	$83.5M-0.4%	$83.8M-0.6%	$84.4M+1026.7%	$7.5M+51.1%	$5.0M
Cash & Equivalents	$2.5M+56163.3%	$4K-92.5%	$59K-63.7%	$163K-55.4%	$367K-44.6%	$662K-80.7%	$3.4M-7.5%	$3.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$37K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$25.8M+1431.7%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M-91.6%	$20.0M+1089.8%	$1.7M
Total Liabilities	$107.5M+17.7%	$91.4M+1.0%	$90.4M+1.3%	$89.3M+15.3%	$77.5M+0.4%	$77.2M+3.0%	$75.0M+2184.9%	$3.3M
Current Liabilities	$33.5M+12.9%	$29.7M+3.3%	$28.7M+4.3%	$27.5M+75.6%	$15.7M+2.0%	$15.4M+149.2%	$6.2M+97.0%	$3.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$6.4M	N/A
Total Equity	$27.9M+542.7%	-$6.3M-20.7%	-$5.2M-34.6%	-$3.9M-146.3%	$8.4M-8.2%	$9.1M-43.6%	$16.2M+349.2%	$3.6M
Retained Earnings	-$205.8M-0.6%	-$204.6M-0.5%	-$203.6M-0.6%	-$202.4M-6.4%	-$190.1M-1.4%	-$187.6M-4.9%	-$178.8M+3.0%	-$184.3M

ENTO Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$9.2M+25.5%	-$12.4M+44.6%	-$22.3M+30.8%	-$32.3M-187.7%	-$11.2M+20.0%	-$14.0M
Capital Expenditures	N/A	N/A	N/A	$69K+1567.6%	$4K-82.7%	$24K
Free Cash Flow	N/A	N/A	N/A	-$32.4M-188.2%	-$11.2M+20.1%	-$14.1M
Investing Cash Flow	$88K+117.6%	-$500K	N/A	-$10.3M-11914.0%	$87K+462.5%	-$24K
Financing Cash Flow	$5.6M-63.3%	$15.2M-3.3%	$15.7M-64.8%	$44.8M+162.6%	$17.0M+29.7%	$13.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$856K-1459.3%	-$55K+93.3%	-$819K-377.3%	-$172K+90.7%	-$1.8M+46.4%	-$3.5M+7.9%	-$3.7M-8.9%	-$3.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	$0	$0	$0-100.0%	$88K	N/A
Financing Cash Flow	$3.0M	$0-100.0%	$700K+2301.4%	-$32K-102.0%	$1.6M+127.9%	$681K-79.8%	$3.4M-22.5%	$4.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ENTO Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-438.4%+95.1pp	-533.5%	N/A	N/A	-328.7%
Return on Assets	-21.1%+208.3pp	-229.5%+39.5pp	-268.9%+227.6pp	-496.5%-243.7pp	-252.8%-82.3pp	-170.5%
Current Ratio	3.03+1.4	1.58+0.2	1.37+0.6	0.77+0.3	0.51-0.3	0.80
Debt-to-Equity	-23.03-23.9	0.91-0.1	0.98+3.5	-2.51+3.4	-5.89-6.8	0.93
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-4.1%	N/A	N/A	N/A	-30.8%+65.7pp	-96.6%-131.0pp	34.4%	N/A
Return on Assets	-0.9%+0.3pp	-1.2%+0.3pp	-1.5%	N/A	-3.0%+7.2pp	-10.2%-16.3pp	6.1%	N/A
Current Ratio	2.62-0.2	2.81-0.1	2.90-0.1	3.03-2.3	5.34-0.1	5.49+4.3	1.21-0.4	1.58
Debt-to-Equity	3.86+18.4	-14.51+2.8	-17.33+5.7	-23.03-32.3	9.25+0.8	8.46+8.1	0.40-0.5	0.91
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$3.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Galecto Inc. GLTO

$1.7B

THERIVA BIOLOGICS INC TOVX

$9.0M

Dermata Therapeutics Inc DRMA

$3.4M

Biodexa Pharmaceuticals plc BDRX

$518K

Silexion Therapeutics Corp SLXN

$4.3M

Frequently Asked Questions

Is Entero Therapeutics profitable?

No, Entero Therapeutics (ENTO) reported a net income of -$18.1M in fiscal year 2024.

What is Entero Therapeutics's EBITDA?

Entero Therapeutics (ENTO) had EBITDA of -$15.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Entero Therapeutics's operating cash flow?

Entero Therapeutics (ENTO) generated -$9.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Entero Therapeutics's total assets?

Entero Therapeutics (ENTO) had $85.4M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Entero Therapeutics spend on research and development?

Entero Therapeutics (ENTO) invested $904K in research and development during fiscal year 2024.

How many shares does Entero Therapeutics have outstanding?

Entero Therapeutics (ENTO) had 2M shares outstanding as of fiscal year 2024.

What is Entero Therapeutics's current ratio?

Entero Therapeutics (ENTO) had a current ratio of 3.03 as of fiscal year 2024, which is generally considered healthy.

What is Entero Therapeutics's debt-to-equity ratio?

Entero Therapeutics (ENTO) had a debt-to-equity ratio of -23.03 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Entero Therapeutics's return on assets (ROA)?

Entero Therapeutics (ENTO) had a return on assets of -21.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Entero Therapeutics's cash runway?

Based on fiscal year 2024 data, Entero Therapeutics (ENTO) had $163K in cash against an annual operating cash burn of $9.2M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Entero Therapeutics's debt-to-equity ratio negative or unusual?

Entero Therapeutics (ENTO) has negative shareholder equity of -$3.9M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Entero Therapeutics's Piotroski F-Score?

Entero Therapeutics (ENTO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Entero Therapeutics's earnings high quality?

Entero Therapeutics (ENTO) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.